Training Program in Pharmacology

药理学培训 摘要： 在药理学（TPPh）这个博士前培训计划的总体目标是教育下一个 在药物发现和开发的概念，包括生物医学研究人员的一代 临床观点该TPPh的四个重点领域是心血管、神经和免疫 疾病和癌症。加州大学戴维斯分校是世界领先的药物开发与多个教练带来的药物 到诊所（最近Rogawski博士的新型产后抗抑郁药Brexanolone）和生物制剂 包括基因治疗载体，正在进行的临床试验超过20项（Nolta主任）。的受训人员 药理学和毒理学，生理学，生物医学工程和神经科学发展专业知识， 不同的领域。领域包括经典药理学和药物靶点识别与尖端方法， 生物化学，结构生物学，基因组学和蛋白质组学，分子和细胞生物学;结构建模和 合理药物设计;药物化学;高分辨成像;电生理学;行为学 生理学;微流体和其他装置的工程;疾病的动物模型;新的体内整体 动物成像;以及临床试验中的转化疗法，包括干细胞和遗传疗法。的 TPPh将在药理学的核心原则方面提供针对性和学生量身定制的小组培训 为非药理学学员，并将这些学生与药理学学生结合起来，进行跨学科的学习。 药物开发中的小组学习一个相关的目标是使所有受训者能够交流和协作 跨越了它们所代表的大量研究学科。这一目标主要是在一个高度创新的 学生驱动的，以项目为导向的课程问题解决在药理学科学，这振兴 根据学生的主动性和兴趣，每年都有自己的活动。通过这种方式，我们的TPPh培养出具有各种 能够与其他相关学科的专家进行有效沟通和合作的背景 在日益复杂的药物开发领域。加州大学戴维斯分校赠款更多的学士和博士学位 生物科学学位比任何其他美国大学。它在校外研究中获得了9.61亿美元 在2020/21年的资金，这地方，像往年一样，在前10名的公立大学。30训练 教师来自6所学院的14个系，已经存在广泛的合作互动。 培训师提供深入的专业知识，从确定新的治疗分子靶点， 在美国国立卫生研究院资助的加州大学戴维斯分校临床实验室开发用于临床药物和干细胞试验的治疗分子 转化科学中心（CTSC）和NIH指定的癌症中心。强大而众多的国家- 最先进的核心设施和中心将为学员提供出色的研究机会， 从化学对药物化学的重视到独特的动物模型（国际公认的 小鼠生物学中心，农业和兽医学校，灵长类动物中心）。

TRAINING PROGRAM IN PHARMACOLOGY ABSTRACT: The overarching goal of this predoctoral Training Program in Pharmacology (TPPh) is to educate next generation of biomedical researchers in the concepts of drug discovery and development, inclusive a clinical perspective. The four focus areas of this TPPh are cardiovascular, neurological, and immunological diseases and cancer. UC Davis is a world leader in drug development with multiple trainers bringing drugs to the clinic (most recently Dr. Rogawski the novel post-partum antidepressant Brexanolone) and biologics including gene therapy vectors with >20 ongoing clinical trials (Director Dr. Nolta). Trainees from Pharmacology & Toxicology, Physiology, Biomedical Engineering and Neuroscience develop expertise in diverse areas. Areas include classic pharmacology & drug target identification with cutting edge methods in biochemistry, structural biology, genomics & proteomics, molecular and cell biology; structural modeling and rational drug design; medicinal chemistry; high & superresolution imaging; electrophysiology; behavioral physiology; engineering of microfluidic and other devices; animal models of disease; novel in vivo whole animal imaging; and translational therapeutics in clinical trials including stem cell and genetic therapies. The TPPh will provide focused and student-tailored small group training in the core principles of pharmacology for non-pharmacology trainees, and enmesh these students with pharmacology students for interdisciplinary group learning in drug development. A related goal is to enable all trainees to communicate and collaborate across the large array of research disciplines they represent. This goal is mainly realized in a highly innovative student-driven, project-oriented course Problem Solving in Pharmacological Sciences, which rejuvenates itself every year based on student initiative and interest. In this way our TPPh produces experts with a variety of backgrounds that can effectively communicate and collaborate with experts from other related disciplines in the increasingly complex realm of drug development. UC Davis grants more bachelors and doctoral degrees in biological sciences than any other U.S. university. It received $961 million in extramural research funding in 2020/21, which places it, as in earlier years, among the top 10 public universities. The 30 training faculty are from 14 departments in 6 colleges, where extensive collaborative interactions already exist. Trainers provide in depth expertise that ranges from identifying novel therapeutic molecular targets and development of therapeutic molecules to clinical drug and stem cell trials at the NIH-funded UC Davis Clinical and Translational Science Center (CTSC) and NIH-designated Cancer Center. Powerful and numerous state- of-the-art core facilities and centers will provide trainees with outstanding research opportunities spanning from Chemistry’s emphasis on pharmaceutical chemistry to unique animal models (internationally recognized mouse biology center, Agricultural & Veterinary Schools, Primate Center).